« IDF Day #4 + #5: final thoughts | Main | Seattle Times on Medtronic - not a case... »



I too wondered about Lilly and any development on a long-acting insulin analog. While they still have a large share of the insulin market, Novo Nordisk and Sanofi-Aventis have really chipped away at that franchise in recent years, as Lilly lost the United Healthcare business in late 2005. From an investment standpoint, Lilly's diabetes business seems to be the one business they have the most risk in because they've really not invested as much there as they should have in recent years, so you're 100% right about them needing Amylin more than the other way around!

The comments to this entry are closed.